Table of Content

1. VISTA: An Emerging Immune Checkpoint
1.1 Introduction to VISTA Inhibition
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism Of Action Of VISTA Inhibitors


2. VISTA Inhibition v/s Conventional Immune Checkpoints Inhibitors


3. Dual Role Of VISTA As Inhibitory & Costimulatory Checkpoint
3.1 VISTA As Inhibitory Immune Checkpoint
3.2 VISTA As Costimulatory Checkpoint


4. Significance Of VISTA In Cancer
4.1 Role Of VlSTA In Facilitating Cancer Progression
4.2 VISTA As Potential Cancer Biomarker


5. VISTA As Therapeutic Target In Autoimmunity


6. Market Potential Of VISTA Inhibitors
6.1 Market Commercialization Assessment Scenario
6.2 Investigational VISTA Inhibitors In Pipeline
6.3 Recent Partnerships, Collaborations & Agreements


7. Global VISTA Inhibitors Clinical Pipeline Overview
7.1 By Biomarker Target
7.2 By Country
7.3 By Indication
7.4 By Organization
7.5 By Phase


8. Global VISTA Inhibitors Clinical Pipeline By Company, Indication & Phase
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase III


9. Global VISTA Inhibitors Market Dynamics
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints


10. Competitive Landscape
10.1 Adimab
10.2 Apexigen
10.3 Aurigene Discovery Technologies
10.4 Cancer Prevention & Research Institute of Texas
10.5 Curis
10.6 Epitomics
10.7 Hummingbird Bioscience
10.8 ImmuNext
10.9 Kineta
10.10 Korea Drug Development Fund
10.11 Merck
10.12 Pierre Fabre
10.13 PharmAbcine
10.14 Sensei Biotherapeutics
10.15 Washington University



List of Figures

Figure 1-1: Structure Of The VISTA Protein
Figure 1-2: Binding Partners For VISTA
Figure 1-3: Basic Mechanism Of VISTA Inhibition

Figure 2-1: Edge Of VISTA Inhibition Over Conventional Checkpoint Inhibition

Figure 7-1: Global – Number Of VISTA Inhibitor Clinical Trials By Biomarker Target, 2023
Figure 7-2: Global – Number Of VISTA Inhibitor Clinical Trials By Country, 2023
Figure 7-3: Global – Number Of VISTA Inhibitor Clinical Trials By Indication, 2023
Figure 7-4: Global – Number Of VISTA Inhibitor Clinical Trials By Organization, 2023
Figure 7-5: Global – Number Of VISTA Inhibitor Clinical Trials By Phase, 2023

Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints